Is The Trade Desk the Best Advertising Stock Now?
The worldly backdrop is now shrouded in heavy uncertainty and…
Sell
27
ZTS Quote, Financials, Valuation and Earnings
Last price:
$156.05
Seasonality move
:
8.76%
Day range:
$152.45 - $154.78
52-week range:
$139.70 - $200.33
Dividend yield:
1.21%
P/E ratio:
28.08x
P/S ratio:
7.55x
P/B ratio:
14.42x
Volume:
1.9M
Avg. volume:
2.7M
1-year change:
-3.06%
Market cap:
$68.8B
Revenue:
$9.3B
EPS (TTM):
$5.47
Analysts' Opinion
-
Consensus RatingZoetis has received a consensus rating of Buy. The company's average rating is a Buy based on 10 Buy ratings, 4 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $195.49, Zoetis has an estimated upside of 27.3% from its current price of $153.57.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $165.00 representing -7.44% downside risk from its current price of $153.57.
Fair Value
-
According to the consensus of 14 analysts, Zoetis has 27.3% upside to fair value with a price target of $195.49 per share.
ZTS vs. S&P 500
-
Over the past 5 trading days, Zoetis has overperformed the S&P 500 by 1.68% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Zoetis does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Zoetis has grown year-over-year revenues for 36 quarters straight. In the most recent quarter Zoetis reported revenues of $2.3B.
Earnings Growth
-
Zoetis has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Zoetis reported earnings per share of $1.29.
Enterprise value:
73.4B
EV / Invested capital:
--
Price / LTM sales:
7.55x
EV / EBIT:
21.84x
EV / Revenue:
7.92x
PEG ratio (5yr expected):
3.56x
EV / Free cash flow:
31.92x
Price / Operating cash flow:
30.40x
Enterprise value / EBITDA:
19.03x
Gross Profit (TTM):
$6.5B
Return On Assets:
17.41%
Net Income Margin (TTM):
26.86%
Return On Equity:
49.71%
Return On Invested Capital:
21.48%
Operating Margin:
33.02%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $8.1B | $8.5B | $9.3B | $2.2B | $2.3B | |
| Gross Profit | $5.6B | $6B | $6.5B | $1.5B | $1.6B | |
| Operating Income | $2.9B | $3.1B | $3.4B | $709M | $765M | |
| EBITDA | $3.3B | $3.7B | $3.9B | $835M | $906M | |
| Diluted EPS | $4.50 | $5.07 | $5.47 | $1.14 | $1.29 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $6.6B | $6.9B | $7.5B | $6.3B | $6B | |
| Total Assets | $13.6B | $13.9B | $14.9B | $14.3B | $14.2B | |
| Current Liabilities | $2.2B | $1.8B | $3.2B | $1.9B | $3.4B | |
| Total Liabilities | $9.8B | $9.4B | $10.5B | $9.3B | $9.5B | |
| Total Equity | $3.8B | $4.5B | $4.4B | $5B | $4.8B | |
| Total Debt | $7.2B | $6.6B | $7.9B | $6.6B | $6.6B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $1.9B | $2.4B | $3B | $897M | $905M | |
| Cash From Investing | -$883M | -$777M | -$315M | -$210M | $126M | |
| Cash From Financing | -$904M | -$3.1B | -$2.7B | -$397M | -$745M | |
| Free Cash Flow | $1.3B | $1.6B | $2.3B | $699M | $689M | |
ZTS
Sector
Market Cap
$68.8B
$34.4M
Price % of 52-Week High
76.66%
44.25%
Dividend Yield
1.21%
0%
Shareholder Yield
3.6%
-0.82%
1-Year Price Total Return
-3.06%
-39.44%
Beta (5-Year)
0.925
0.738
Dividend yield:
1.21%
Annualized payout:
$1.73
Payout ratio:
31.62%
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$150.32
200-day SMA
Sell
Level
$174.36
Bollinger Bands (100)
Sell
Level
156.36 - 173.06
Chaikin Money Flow
Buy
Level
235.4M
20-day SMA
Buy
Level
$152.37
Relative Strength Index (RSI14)
Sell
Level
48.52
ADX Line
Sell
Level
21.96
Williams %R
Sell
Level
-8.0239
50-day SMA
Sell
Level
$159.36
MACD (12, 26)
Sell
Level
-2.58
25-day Aroon Oscillator
Sell
Level
-16
On Balance Volume
Neutral
Level
182.6M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (7.4533)
Buy
CA Score
(Annual)
Level (0.1275)
Buy
Beneish M-Score
(Annual)
Level (-2.6133)
Buy
Momentum Score
Level (4)
Buy
Ohlson Score
Level (-0.7806)
Buy
Piotroski F Score
(Annual)
Level (8)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (10)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its us business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Stock Forecast FAQ
In the current month, ZTS has received 10 Buy ratings 4 Hold ratings, and 0 Sell ratings. The ZTS average analyst price target in the past 3 months is $195.49.
-
Where Will Zoetis Stock Be In 1 Year?
According to analysts, the consensus estimate is that Zoetis share price will rise to $195.49 per share over the next 12 months.
-
What Do Analysts Say About Zoetis?
Analysts are divided on their view about Zoetis share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Zoetis is a Sell and believe this share price will drop from its current level to $165.00.
-
What Is Zoetis's Price Target?
The price target for Zoetis over the next 1-year time period is forecast to be $195.49 according to 14 Wall Street analysts, 10 of them rate the stock a Buy, 0 rate the stock a Sell, and 4 analysts rate the stock a Hold.
-
Is ZTS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Zoetis is a Buy. 10 of 14 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ZTS?
You can purchase shares of Zoetis via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Zoetis shares.
-
What Is The Zoetis Share Price Today?
Zoetis was last trading at $156.05 per share. This represents the most recent stock quote for Zoetis. Yesterday, Zoetis closed at $153.57 per share.
-
How To Buy Zoetis Stock Online?
In order to purchase Zoetis stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is it Too Late to Buy Gold?
Amid deep uncertainties about the future of the US economy,…
Is NextEra Energy a Stock to Hold Forever?
NextEra Energy (NYSE:NEE) share price sold off hard in recent…
Stock Ideas
Buy
61
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
54
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Sell
39
RGC alert for Apr 29
Regencell Bioscience Holdings [RGC] is down 9.73% over the past day.
Buy
76
EXOD alert for Apr 29
Exodus Movement [EXOD] is down 1.99% over the past day.
Sell
48
SBGSY alert for Apr 29
Schneider Electric SE [SBGSY] is down 0.11% over the past day.
